This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling

Stocks in this article: BPAXINHXIDIXCYCCZIOPONTY

BOSTON ( TheStreet) -- More noteworthy hedge fund trading across the biotech sector, culled from the most recent crop of 13Fs:

  • BioSante Pharmaceuticals (BPAX) looks like it's becoming a crowded hedge fund long. I count ten new positions (greater than 300,000 shares) established in the third quarter, most notably 1.77 million shares purchased by Jennison Associates. Manatuck Hill Partners also stepped up to buy 1.5 million first-time BioSante shares.

    All this buying makes me suspect hedge funds are lining up short-term rentals to play the release of efficacy data from Biosante's phase III trials of Libigel to be announced in December. Libigel is a low-dose testosterone gel being developed to boost the libido of menopausal women.

    Or maybe the six funds that sold an aggregate 4.89 million shares of BioSante in the third quarter (including five funds that zeroed out their entire positions) know better?

  • Idenix Pharmaceuticals (IDIX), the developer of hepatitis C drugs, saw some substantial buying led by Fidelity, which added another 2.7 million shares in the September quarter. Fidelity now owns 7.3 million shares. Westfield Capital Management added 1.9 million shares to turn what was a small position into a large one.

    Brookside Capital made a big bet on Idenix in the second quarter, buying up 9.1 million shares. That position has grown to almost 11 million shares at the end of the third quarter.

    On the other side of the trade, Orbimed liquidated a 2.7 million-share stake in Idenix, while Columbia Wanger also zeroed out, shedding 2.6 million shares.

    Idenix is expected to announce crucial phase IIb data on its nucleotide inhibitor IDX184 in January.

  • A missed opportunity in Inhibitex (INHX)? Wellington Management sold 1.7 million shares, Baker Brothers sold 781,000 shares (exiting the position), in the third quarter. A month later, Inhibitex shares doubled in value on the release of promising new data on its hepatitis C drug INX-189.
  • Cyclacel Pharmaceuticals (CYCC) lost one of its largest, long-time shareholders. Austin Marxe and David Greenhouse, also known as Special Situations Fund, sold 3.95 million shares in the quarter to eliminate its stake in the company entirely.

    Stepping in with new buys were Ayer Capital (1.31 million shares) and RedMile Group (1.15 million shares.)

  • Seven funds liquidated positions in Ziopharm Oncology (ZIOP) during the third quarter, although four of those sales were from relatively small positions that could have been boxes against a short.
  • For most of the spring, Oncothyreon (ONTY) was riding a hot wave as the next Dendreon (DNDN), its lung cancer immunotherapy Stimuvax being compared favorably to Provenge. Today, no one wants to be the next Dendreon, which may explain why Oncothyreon's buzz has cooled considerably.

    Black Horse Capital sold its entire 1.12-million share stake in Oncothyreon during the third quarter -- a position the fund only established in the second quarter.

    Four other funds liquidated Oncothyreon positions in the September quarter, including Ayer Capital, sellers of 888,000 shares.

    The largest new buyer of Oncyothreon during the third quarter was Viking Global Investors, which added 3.1 million shares.

  • I already wrote about SAC Capital Advisors dumping more than 8 million shares of Dendreon during the quarter, but what other biotech stocks did billionaire hedge fund manager Steven Cohen trade?

    Some of Cohen's new biotech buys include Idenix Pharmaceuticals (IDIX) (+301,000 shares) and Dynavax Technologies (DVAX) (+3 million shares.)

    Cohen dumped positions in Savient Pharmaceuticals (SVNT) and Ista Pharmaceuticals (ISTA) and reduced stakes in United Therapeutics (UTHR), Amylin Pharmaceuticals (AMLN) and Acorda Therapeutics (ACOR).

  • To learn more about which biotech stocks were bought and sold during the third quarter, read 10 Biotech Stocks Loved and Hated by Wall Street's Top Investment Pros.

    And to see these stocks in action, visit the 13 Biotech Stocks Bought and Sold by Hedge Funds portfolio on Stockpickr.

    --Written by Adam Feuerstein in Boston.



    >To contact the writer of this article, click here: Adam Feuerstein.

    >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

    >To submit a news tip, send an email to: tips@thestreet.com.

    Follow TheStreet on Twitter and become a fan on Facebook.

    Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

    Select the service that is right for you!

    COMPARE ALL SERVICES
    Action Alerts PLUS
    Try it NOW

    Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    • Weekly roundups
    TheStreet Quant Ratings
    Try it NOW
    Only $49.95/yr

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    • Upgrade/downgrade alerts
    Stocks Under $10
    Try it NOW

    David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    • Weekly roundups
    Dividend Stock Advisor
    Try it NOW

    Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Alerts when market news affect the portfolio
    • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
    Real Money Pro
    Try it NOW

    All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

    Product Features:
    • Real Money + Doug Kass Plus 15 more Wall Street Pros
    • Intraday commentary & news
    • Ultra-actionable trading ideas
    Options Profits
    Try it NOW

    Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

    Product Features:
    • 100+ monthly options trading ideas
    • Actionable options commentary & news
    • Real-time trading community
    • Options TV
    To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
    Submit an article to us!
    DOW 16,805.41 +127.51 0.76%
    S&P 500 1,964.58 +13.76 0.71%
    NASDAQ 4,483.7150 +30.9230 0.69%

    Brokerage Partners

    Rates from Bankrate.com

    • Mortgage
    • Credit Cards
    • Auto

    Free Newsletters from TheStreet

    My Subscriptions:

    After the Bell

    Before the Bell

    Booyah! Newsletter

    Midday Bell

    TheStreet Top 10 Stories

    Winners & Losers

    Register for Newsletters
    Top Rated Stocks Top Rated Funds Top Rated ETFs